[go: up one dir, main page]

BG100236A - Sheared keratiocytic growth factor (kgf) of increased biological activity - Google Patents

Sheared keratiocytic growth factor (kgf) of increased biological activity

Info

Publication number
BG100236A
BG100236A BG100236A BG10023695A BG100236A BG 100236 A BG100236 A BG 100236A BG 100236 A BG100236 A BG 100236A BG 10023695 A BG10023695 A BG 10023695A BG 100236 A BG100236 A BG 100236A
Authority
BG
Bulgaria
Prior art keywords
kgfdesl
growth factor
relates
keratiocytic
sheared
Prior art date
Application number
BG100236A
Other languages
Bulgarian (bg)
English (en)
Inventor
Denis Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of BG100236A publication Critical patent/BG100236A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
BG100236A 1993-06-29 1995-12-20 Sheared keratiocytic growth factor (kgf) of increased biological activity BG100236A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (1)

Publication Number Publication Date
BG100236A true BG100236A (en) 1996-07-31

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100236A BG100236A (en) 1993-06-29 1995-12-20 Sheared keratiocytic growth factor (kgf) of increased biological activity

Country Status (25)

Country Link
US (7) US5677278A (xx)
EP (2) EP1493812A3 (xx)
JP (4) JP3570516B2 (xx)
KR (1) KR960703433A (xx)
CN (1) CN1129955A (xx)
AT (1) ATE278777T1 (xx)
AU (1) AU681405B2 (xx)
BG (1) BG100236A (xx)
BR (1) BR9407035A (xx)
CA (1) CA2166278A1 (xx)
CZ (1) CZ343795A3 (xx)
DE (2) DE122006000005I2 (xx)
DK (1) DK0706563T3 (xx)
ES (1) ES2227527T3 (xx)
FI (1) FI956203A7 (xx)
FR (1) FR06C0004I2 (xx)
HU (1) HUT73453A (xx)
LU (1) LU91215I2 (xx)
NL (1) NL300217I2 (xx)
NO (1) NO955189D0 (xx)
NZ (1) NZ266622A (xx)
PL (1) PL312257A1 (xx)
PT (1) PT706563E (xx)
SK (1) SK153295A3 (xx)
WO (1) WO1995001434A1 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
ES2153816T3 (es) * 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
EP1493812A3 (en) 1993-06-29 2006-02-08 Chiron Corporation A truncated keratinocyte growth factor (KGF) having increased biological activity
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
PT785949E (pt) * 1994-10-13 2003-09-30 Amgen Inc Metodo para purificar factores de crescimento de queratinocitos
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
BR9509269A (pt) * 1994-10-13 1997-12-23 Amgen Inc Processo para tratar diabetes
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
PT871730E (pt) * 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
ATE263239T1 (de) * 1996-10-15 2004-04-15 Amgen Inc Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU7970498A (en) * 1997-06-19 1999-01-04 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20010033484A (ko) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
KR20010040906A (ko) * 1998-02-13 2001-05-15 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2의 치료학적 용도
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
JP4262979B2 (ja) 2000-11-21 2009-05-13 ザ・テキサス・エイ・アンド・エム・ユニバーシテイ・システム Ｆｇｆアフィニティークロマトグラフィー
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
PL374269A1 (en) * 2001-08-21 2005-10-03 Chiron Corporation Kgf polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CA2589889C (en) * 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
EP4219708A3 (en) 2009-07-17 2023-10-11 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
RU2016117275A (ru) 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
JP2024532086A (ja) 2021-08-30 2024-09-05 ユニケム ラボラトリーズ リミテッド 炎症性疾患の処置のためのタンパク質組成物
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
EP1493812A3 (en) 1993-06-29 2006-02-08 Chiron Corporation A truncated keratinocyte growth factor (KGF) having increased biological activity
BR9509269A (pt) 1994-10-13 1997-12-23 Amgen Inc Processo para tratar diabetes
PT785950E (pt) 1994-10-13 2003-09-30 Amgen Inc Analogos do factor de crescimento de queratinocitos

Also Published As

Publication number Publication date
CZ343795A3 (en) 1996-07-17
DK0706563T3 (da) 2005-01-31
DE122006000005I2 (de) 2006-11-23
FR06C0004I1 (xx) 2006-03-10
KR960703433A (ko) 1996-08-17
SK153295A3 (en) 1996-11-06
JP2004166709A (ja) 2004-06-17
US6677301B1 (en) 2004-01-13
DE122006000005I1 (de) 2006-08-10
FR06C0004I2 (fr) 2006-12-29
PL312257A1 (en) 1996-04-01
ATE278777T1 (de) 2004-10-15
AU6820894A (en) 1995-01-24
JP3570516B2 (ja) 2004-09-29
US6074848A (en) 2000-06-13
NO955189L (no) 1995-12-20
CA2166278A1 (en) 1995-01-12
CN1129955A (zh) 1996-08-28
LU91215I2 (en) 2006-03-27
PT706563E (pt) 2005-01-31
JPH09500267A (ja) 1997-01-14
WO1995001434A1 (en) 1995-01-12
DE69434053T2 (de) 2006-02-23
US5863767A (en) 1999-01-26
AU681405B2 (en) 1997-08-28
EP1493812A3 (en) 2006-02-08
DE69434053D1 (de) 2005-01-20
FI956203A0 (fi) 1995-12-22
HUT73453A (en) 1996-08-28
NL300217I1 (nl) 2006-04-03
EP0706563A1 (en) 1996-04-17
BR9407035A (pt) 1996-03-12
US5677278A (en) 1997-10-14
HU9503857D0 (en) 1996-02-28
NO955189D0 (no) 1995-12-20
ES2227527T3 (es) 2005-04-01
US20090093400A1 (en) 2009-04-09
EP1493812A2 (en) 2005-01-05
JP2009062396A (ja) 2009-03-26
NL300217I2 (nl) 2006-05-01
FI956203A7 (fi) 1996-02-07
EP0706563B1 (en) 2004-10-06
NZ266622A (en) 1997-10-24
JP4662569B2 (ja) 2011-03-30
US5773586A (en) 1998-06-30
US5843883A (en) 1998-12-01
JP2006075173A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
DE3650055T2 (de) Fibroblast-wachstumsfaktor.
AU704515C (en) Novel protein and process for producing the same
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
CA2223433A1 (en) Ob protein compositions and methods
ES2084045T3 (es) Bacterias que albergan vectores de expresion que codifican el factor neurotrofico ciliar humano (h-cntf), su uso en la produccion de h-cntf, anticuerpos para h-cntf y el uso de h-cntf en el tratamiento medico.
JPH02504279A (ja) インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド
AU3368497A (en) Human dnase i hyperactive variants
WO1995021919A3 (en) Protein having tpo activity
EP0821006A2 (de) Insulinderivate mit erhöhter Zinkbindung
JPS62501609A (ja) ヒト成長ホルモンの製造方法
DE69029415T2 (de) Osteogenische Wachstumfaktoren, die aus sich regenerierendem Knochenmark identifiziert werden
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
WO1993019084A1 (en) Refolding and purification of insulin-like growth factor i
HRP940432B1 (en) Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
EP0241136A3 (en) Human class 1 heparin-binding growth factor
AU7430500A (en) Monomeric analogues of human insulin
RU95101042A (ru) Рекомбинантный полипептид, антисыворотки, фармацевтическая композиция, способ ингибирования транспорта катионных аминокислот, способ ингибирования продукции окиси азота, способ лечения
DE69730967D1 (en) Human dnase ii
ZA961419B (en) Human DNase I variants.
WO1991006560A1 (de) Quervernetzte tumor-nekrose-faktoren
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same
MX9800686A (es) Nueva proteina hmw humana mp52s.
JPS63316798A (ja) 新規なペプチド及びこれを有効成分とする創傷治療剤
RU96104372A (ru) НОВЫЙ ФАКТОР РОСТА / ДИФФЕРЕНЦИАЦИИ TGF-β--СЕМЕЙСТВА